The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
989
December 6, 1996
View Complete Issue         Table of Contents 2019 
Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder
December 6, 1996 (Issue: 989)
Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder (ADHD).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder
Article code: 989c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.